Biomatlante is very pleased to announce the acquisition of 100% of its shares by Advanced Medical Solutions Group plc (London Alternative Investment Market: AMS).
The acquisition will strengthen AMS’s product portfolio, R&D pipeline, and market access. It provides the Group with a range of revenue-generating surgical products and an R&D pipeline of complementary biosurgical technologies and offers significant growth potential in additional surgical markets estimated to be worth $0.5 billion. Biomatlante platform technologies will broaden the Group’s biosurgical technology offering while also offering multiple synergies across the sales, marketing, regulatory, operational divisions and R&D.
Commenting this acquisition, Chantal Gobin-Daculsi, Co-founder and President of Biomatlante said: “This is an important strategic step for Biomatlante and we are excited to become part of the AMS group. AMS is a highquality global Company with the scale, expertise and track record of realising the value of scientific innovation and rapidly growing the sales of marketed products. As now part of the AMS family, the know-how of our team can be fully realised to pursue Biomatlante’s continued growth in innovative bone regenerative technologies.”